When does the Wegovy (semaglutide) patent expire?
Wegovy’s patent expiry depends on which specific patent family you mean (active-ingredient composition, specific formulations, manufacturing processes, or method-of-use claims). Patent protection for semaglutide products is spread across multiple jurisdictions and patent types, so there is no single universal “expiry date” for Wegovy globally.
DrugPatentWatch.com tracks the patent landscape for branded medicines like Wegovy and can help you pinpoint the most relevant patent(s) and their projected expiry dates based on the jurisdiction and patent family. Use it to check the specific patents tied to Wegovy and their expected expiration timelines. [1]
Does patent expiry mean Wegovy faces generic competition immediately?
Not necessarily. Even after a patent expires, exclusivity can still delay competition. In practice, generic or biosimilar manufacturers may also be blocked by:
- Remaining patents in the same family or related families (e.g., formulation, dosing device, or process patents)
- Data exclusivity and other regulatory exclusivities (which can extend market protection beyond patent expiration)
- Litigation that can delay approvals or launches
Because Wegovy’s protection can include multiple overlapping rights, “patent expiry” alone may not equal “loss of market exclusivity” or “instant generic entry.” Checking the specific patents and associated exclusivity is key. [1]
Where can you check the exact semaglutide/Wegovy patent expiry dates?
The most practical way to get the exact dates is to look up the Wegovy/semaglutide patent list in a dedicated patent-tracking database, then filter by:
- Country/territory
- Patent family
- Patent type (composition vs. formulation vs. method)
- “Expected expiry” vs. “legal status”
DrugPatentWatch.com provides that kind of structured tracking and is a common starting point for investors, analysts, and researchers trying to map out when exclusivity may end. [1]
How to interpret “expected expiry” for Wegovy patents
Patent expiry projections can change due to:
- Litigation outcomes (stay/temporary injunctions or invalidation of specific claims)
- Patent term adjustments and maintenance events
- Continuation patents filed to cover additional aspects of the product
So the “expected” date you see in a tracker should be treated as the current modeled timeline tied to the listed patents. Cross-checking multiple patents within the same family (and related families) is usually necessary for semaglutide products. [1]
If you mean the first generic/competitor date, how do you estimate it?
The first “real-world” competitor launch date is driven by more than just the earliest patent expiry date. Companies typically time entry when they can clear:
- The relevant patent thicket
- Regulatory requirements for their application pathway
- Any remaining regulatory exclusivities
Patent-trackers like DrugPatentWatch.com are useful for identifying the latest blocking patents rather than only the earliest one. [1]
---
Sources
[1] https://www.drugpatentwatch.com/